Castle Biosciences, Inc. (CSTL)

Castle Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-5.07	18.25	-57.47	-67.14	-31.29	-10.28
Depreciation & Amortization	42.42	16	12.33	10.54	3.41	0.47
Other Amortization	-	-	-	-	-	0.84
Loss (Gain) From Sale of Investments	-5.55	-7.24	-5.49	-1.37	-	-
Stock-Based Compensation	48.82	50.32	51.22	36.32	21.74	8.31
Other Operating Activities	0.75	1.67	0.41	-20.01	-8.74	1.38
Change in Accounts Receivable	-13.6	-12.64	-14.93	-6.22	-4.63	1.66
Change in Inventory	0.8	-0.19	-3.96	-1.68	0.33	-0.98
Change in Accounts Payable	-3.34	-4.37	5.71	0.58	-0.18	0.17
Change in Other Net Operating Assets	0.43	3.08	6.56	7.31	0.38	8.3
Operating Cash Flow	65.67	64.87	-5.63	-41.66	-18.98	9.87
Operating Cash Flow Growth	405.97%	-	-	-	-	40.63%
Capital Expenditures	-23.91	-28.33	-13.62	-5.63	-3.48	-4.75
Sale of Property, Plant & Equipment	0.02	0.02	0.01	0.2	0.01	0
Cash Acquisitions	-	-	-	-26.42	-63.18	-
Investment in Securities	-28.98	-21.83	-2.58	-134.69	-	-
Investing Cash Flow	-52.87	-50.14	-16.18	-166.55	-66.66	-4.75
Long-Term Debt Issued	-	10	-	-	-	-
Total Debt Issued	-	10	-	-	-	-
Long-Term Debt Repaid	-	-0.1	-0.14	-0.12	-0.01	-27.36
Total Debt Repaid	-0.09	-0.1	-0.14	-0.12	-0.01	-27.36
Net Debt Issued (Repaid)	-0.09	9.9	-0.14	-0.12	-0.01	-27.36
Issuance of Common Stock	4.83	5	2.98	3.33	6.55	333.25
Repurchase of Common Stock	-10.8	-8.76	-5.13	-1.69	-0.78	-
Other Financing Activities	-	-	-	-	-0.34	-
Financing Cash Flow	-6.06	6.14	-2.3	1.52	5.42	305.89
Net Cash Flow	6.74	20.87	-24.11	-206.69	-80.22	311.01
Free Cash Flow	41.75	36.54	-19.25	-47.29	-22.47	5.11
Free Cash Flow Growth	-	-	-	-	-	-15.86%
Free Cash Flow Margin	12.03%	11.00%	-8.76%	-34.51%	-23.88%	8.16%
Free Cash Flow Per Share	1.49	1.25	-0.72	-1.81	-0.89	0.27
Cash Interest Paid	0.43	0.43	0.01	0.02	0	1.98
Cash Income Tax Paid	2.5	2.5	0.2	0.12	0.02	0.1
Levered Free Cash Flow	44.64	29.45	0.82	-14.69	-5.03	7.47
Unlevered Free Cash Flow	45	29.81	0.83	-14.68	-5.03	8.28
Change in Net Working Capital	13.71	13.6	6.62	-1.05	1.64	-9.51

Updated May 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q